Peptides DB

Research-centric peptide and protocol reference hub

Tesofensine

Research-centric overview

Share
Peptide

Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).

Community effect votes, structured logs, and side-effect summaries.
No effect profile data seeded yet for this peptide.

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Apr 17, 2026
1
Studies indexed
0
Human
0
Animal
0
AI analyzed
Evidence mix0% human · 0% animal · 0% cellular · 0% review
Highest phase: Preclinical onlyYears covered: —

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Two-center, Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus (T2DM)Clinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the safety and efficacy of co-administration of Tesofensine and Metoprolol in subjects with Type 2 Diabetes Mellitus (T2DM). The specific doses and outcomes were not detailed in the abstract. The study aimed to determine the effects of this combination treatment on patients with T2DM.

Phase: PHASE2Status: COMPLETED
A 24-week Phase 2, Double-blind, Randomized, Placebo- Controlled, Single-center Safety and Efficacy Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO), and With a 24-week Open-label Extension, in Total 48 WeeksClinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the safety and tolerability of co-administration of Tesofensine and Metoprolol in subjects with hypothalamic injury-induced obesity over 48 weeks. The study included a 24-week double-blind randomized placebo-controlled phase followed by a 24-week open-label extension. No therapeutic claims are made regarding the outcomes.

Phase: PHASE2Status: COMPLETED
A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)Clinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the efficacy and safety of NS 2330 in early Parkinson's disease patients over a fourteen-week period. The study involved a placebo-controlled, dose-response design. No therapeutic claims are made regarding the outcomes.

Phase: PHASE2Status: COMPLETED
The Effect of Tesofensine on Energy Balance in Humans. A Randomised, Double-Blind, Placebo-Controlled, Parallel- Group, Single Centre Study.Clinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the effect of Tesofensine on energy balance in humans through a randomized, double-blind, placebo-controlled design. The specific population, dose, and outcomes were not detailed in the abstract. The findings regarding energy balance were not reported in the abstract.

Phase: PHASE1, PHASE2Status: COMPLETED
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS)Clinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the efficacy and safety of NS 2330 (tesofensine) at doses of 0.125 mg, 0.25 mg, 0.5 mg, and 1.0 mg administered orally once daily over 14 weeks in levodopa-treated Parkinson's disease patients experiencing motor fluctuations. The study aimed to explore the potential of NS 2330 as a treatment option. No therapeutic claims are made.

Phase: PHASE2Status: COMPLETED
Semantic Scholar search for TesofensineStudySemanticScholarDec 12, 2025

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Comments appear immediately.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.